Business
SOPHiA GENETICS Announces Expansion of Work with CHU de Nîmes
Through the expanded relationship CHU de Nîmes will advance its research of rare and inherited diseases through pharmacogenomics BOSTON and ROLLE,
About this update from Sophia Genetics Sa
[{"type":"text","content":"Through the expanded relationship CHU de Nîmes will advance its research of rare and inherited diseases through pharmacogenomics\nBOSTON and ROLLE, Switzerland, Nov. 30, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France. The hospital system will use the SOPHiA DDM™ Platform to progress its pharmacogenomics research.\n\n \n \n \n \n \n \n\n \nPharmacogenomics research is a field of research that looks at how an individual's unique genetic profile can affect response to medications, with the long-term goal to support clinicians in their choice of drugs and doses to best treat their patients.\n\"As precision medicine continues to become the gold standard of care, it's essential that hospitals and organizations like CHU de Nîmes have access to technologies to help streamline research and treatment planning, starting with identifying how an individual's genetic profile influences response to a certain medication\" said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. \"With the SOPHiA DDM™ Platform, CHU de Nîmes will be able to advance its pharmacogenomics work, with the aim to bring about a broader use of personalized treatment plans for the French patient population.\"\nCHU de Nîmes is a member of the French-speaking group RNPGx, an international organization of some of the top researchers in the field of pharmacogenomics. RNPGx aims to further the adoption and implementation of pharmacogenetics testing.\nTop researchers from RNPGx member institutions collaborated with SOPHiA GENETICS to develop a pharmacogenomics panel. The panel is a targeted, capture-based NGS panel that will expedite the process of testing and accelerate pharmacogenomics research. Additionally, the analytical capabilities of the SOPHiA DDM ™ Platform provide CHU de Nîmes with streamlined insights to facilitate fast and accurate variant discovery and reporting.\nCHU de Nîmes also uses SOPHiA GENETICS' technology for its research and treatment planning for autism and research of blood cancers. With the expanded relationship, CHU de Nîmes will continue to retain ownership of its research database, building upon the work already done through its use of SOP...